| 18.33 -0.25 (-1.35%) | 12-26 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 22.66 | 1-year : | 24.52 |
| Resists | First : | 19.4 | Second : | 21 |
| Pivot price | 17.99  |
|||
| Supports | First : | 16.81 | Second : | 13.99 |
| MAs | MA(5) : | 18.02 |
MA(20) : | 18.47 |
| MA(100) : | 27.4 |
MA(250) : | 0 | |
| MACD | MACD : | -1.2 |
Signal : | -1.5 |
| %K %D | K(14,3) : | 38.5 |
D(3) : | 32.6 |
| RSI | RSI(14): 40.3 |
|||
| 52-week | High : | 44.34 | Low : | 16.81 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ ZLAB ] has closed below upper band by 38.3%. Bollinger Bands are 50.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 1 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 18.59 - 18.68 | 18.68 - 18.77 |
| Low: | 17.79 - 17.91 | 17.91 - 18.02 |
| Close: | 18.12 - 18.3 | 18.3 - 18.48 |
Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience primarily in Mainland China and Hong Kong. The company's commercial products include Zejula, a once-daily small-molecule poly polymerase 1/2 inhibitor; Optune, a device that delivers tumor treating fields; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; and Qinlock to treat gastrointestinal stromal tumors. It also develops Odronextamab to treat follicular lymphoma, diffuse large B-cell lymphoma, and other B-celllymphomas; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Margetuximab for the treatment of breast and gastroesophageal cancers; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, pancreatic cancer, and other solid tumors; and Bemarituzumab to treat gastric and gastroesophageal junction cancer. In addition, the company develops CLN-081 for the treatment of patients with EGFR exon 20 insertion NSCLC; Elzovantinib, an orally bioavailable multi-targeted kinase inhibitor; Tebotelimab, a tetravalent IgG4 monoclonal antibody; Retifanlimab that inhibits interactions between PD-1 and its ligands; ZL-2309, an orally active, selective, and ATP-competitive cell division cycle 7 (CDC7) kinase inhibitor; ZL-1201, a humanized IgG4 monoclonal antibody; Efgartigimod to reduce disease-causing immunoglobulin G antibodies; ZL-1102, a human nanobody targeting interleukin- 17A; KarXT for the treatment of psychiatric and neurological conditions; ZL-2313, an investigational inhibitor of triple-mutant EGFR harboring; ZL-2314, an investigational inhibitor of double-mutant EGFR harboring; and Sulbactam/durlobactam for the treatment of serious infections caused by Acinetobacter. Zai Lab Limited was incorporated in 2013 and is headquartered in Shanghai, China.
Wed, 24 Dec 2025
Zai Lab (NASDAQ:ZLAB) Shares Gap Up - Time to Buy? - MarketBeat
Wed, 24 Dec 2025
ZLAB Stock Rises 7.4% Amid Positive Momentum - GuruFocus
Tue, 23 Dec 2025
Price-Driven Insight from (ZLAB) for Rule-Based Strategy - Stock Traders Daily
Tue, 23 Dec 2025
Zai Lab Secures China's Approval For Schizophrenia Therapy In Adults - Nasdaq
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 111 (M) |
| Shares Float | 1,090 (M) |
| Held by Insiders | 1.7 (%) |
| Held by Institutions | 35.5 (%) |
| Shares Short | 5,040 (K) |
| Shares Short P.Month | 5,020 (K) |
| EPS | -1.9 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 6.86 |
| Profit Margin | -46.9 % |
| Operating Margin | -42.1 % |
| Return on Assets (ttm) | -13.3 % |
| Return on Equity (ttm) | -29 % |
| Qtrly Rev. Growth | 13.5 % |
| Gross Profit (p.s.) | 0.36 |
| Sales Per Share | 3.99 |
| EBITDA (p.s.) | -1.94 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -181 (M) |
| Levered Free Cash Flow | -181 (M) |
| PE Ratio | -9.65 |
| PEG Ratio | 0 |
| Price to Book value | 2.66 |
| Price to Sales | 4.59 |
| Price to Cash Flow | -11.23 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|